Octreopharm

BERLIN, October 12, 2011 - OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.

BERLIN, October 6, 2011 - OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.